hepatitis B surface antigen vaccine 20 MCG in 0.5 ML Prefilled Syringe
PSN
10
These highlights do not include all the information needed to use HEPLISAV-B ® safely and effectively. See full prescribing information for HEPLISAV-B. HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] injection, for intramuscular use Initial U.S. Approval: 2017
hepatitis B surface antigen vaccine 0.04 MG/ML per 0.5 ML Prefilled Syringe
SY
10
These highlights do not include all the information needed to use HEPLISAV-B ® safely and effectively. See full prescribing information for HEPLISAV-B. HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] injection, for intramuscular use Initial U.S. Approval: 2017
0.5 ML hepatitis B surface antigen vaccine 0.04 MG/ML Prefilled Syringe
SCD
10
These highlights do not include all the information needed to use HEPLISAV-B ® safely and effectively. See full prescribing information for HEPLISAV-B. HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] injection, for intramuscular use Initial U.S. Approval: 2017
0.5 ML hepatitis B surface antigen vaccine 0.04 MG/ML Prefilled Syringe
SCD
10
These highlights do not include all the information needed to use HEPLISAV-B ® safely and effectively. See full prescribing information for HEPLISAV-B. HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] injection, for intramuscular use Initial U.S. Approval: 2017
hepatitis B surface antigen vaccine 20 MCG in 0.5 ML Prefilled Syringe
PSN
10
These highlights do not include all the information needed to use HEPLISAV-B ® safely and effectively. See full prescribing information for HEPLISAV-B. HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] injection, for intramuscular use Initial U.S. Approval: 2017
hepatitis B surface antigen vaccine 0.04 MG/ML per 0.5 ML Prefilled Syringe
SY
10
These highlights do not include all the information needed to use HEPLISAV-B ® safely and effectively. See full prescribing information for HEPLISAV-B. HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] injection, for intramuscular use Initial U.S. Approval: 2017
hepatitis B surface antigen vaccine 20 MCG in 0.5 ML Prefilled Syringe
PSN
5
These highlights do not include all the information needed to use HEPLISAV-B ® safely and effectively. See full prescribing information for HEPLISAV-B. HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] Solution for Intramuscular Injection Initial U.S. Approval: 2017
0.5 ML hepatitis B surface antigen vaccine 0.04 MG/ML Prefilled Syringe
SCD
5
These highlights do not include all the information needed to use HEPLISAV-B ® safely and effectively. See full prescribing information for HEPLISAV-B. HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] Solution for Intramuscular Injection Initial U.S. Approval: 2017
hepatitis B surface antigen vaccine 0.04 MG/ML per 0.5 ML Prefilled Syringe
SY
5
These highlights do not include all the information needed to use HEPLISAV-B ® safely and effectively. See full prescribing information for HEPLISAV-B. HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] Solution for Intramuscular Injection Initial U.S. Approval: 2017